Patents by Inventor Yasunori Mitsuoka

Yasunori Mitsuoka has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11041152
    Abstract: The purpose of the present invention is to provide novel miR-143 derivatives described herein that can be used as oligonucleotide therapeutics.
    Type: Grant
    Filed: April 13, 2017
    Date of Patent: June 22, 2021
    Assignees: E-NA BIOTEC INC.
    Inventors: Yukihiro Akao, Yukio Kitade, Mitsuaki Sekiguchi, Yasunori Mitsuoka, Akira Kugimiya, Yasuo Sasaki
  • Patent number: 10940201
    Abstract: The purpose of the present invention is to provide double-stranded oligonucleotides comprising the CpG oligonucleotide mentioned below, as a nucleic acid derivative having an immunostimulatory activity. An adjuvant comprising a double-stranded oligonucleotide, wherein a first strand is a CpG oligonucleotide consisting of 8 to 50 nucleotides, a second strand is an oligonucleotide consisting of 8 to 60 nucleotides and comprising a sequence capable of hybridizing with the first strand, and a lipid binds to the second strand through a linker.
    Type: Grant
    Filed: February 28, 2018
    Date of Patent: March 9, 2021
    Assignee: SHIONOGI & CO., LTD.
    Inventors: Akira Kugimiya, Tetsuya Tanino, Mitsuaki Sekiguchi, Yasunori Mitsuoka, Norikazu Kuroda, Jun Nakamura
  • Publication number: 20190119677
    Abstract: The purpose of the present invention is to provide novel miR-143 derivatives described herein that can be used as oligonucleotide therapeutics.
    Type: Application
    Filed: April 13, 2017
    Publication date: April 25, 2019
    Applicant: Shionogi & Co., Ltd.
    Inventors: Yukihiro AKAO, Yukio KITADE, Mitsuaki SEKIGUCHI, Yasunori MITSUOKA, Akira KUGIMIYA, Yasuo SASAKI
  • Publication number: 20180264105
    Abstract: The purpose of the present invention is to provide double-stranded oligonucleotides comprising the CpG oligonucleotide mentioned below, as a nucleic acid derivative having an immunostimulatory activity. An adjuvant comprising a double-stranded oligonucleotide, wherein a first strand is a CpG oligonucleotide consisting of 8 to 50 nucleotides, a second strand is an oligonucleotide consisting of 8 to 60 nucleotides and comprising a sequence capable of hybridizing with the first strand, and a lipid binds to the second strand through a linker.
    Type: Application
    Filed: February 28, 2018
    Publication date: September 20, 2018
    Applicant: Shionogi & Co., Ltd.
    Inventors: Akira KUGIMIYA, Tetsuya TANINO, Mitsuaki SEKIGUCHI, Yasunori MITSUOKA, Norikazu KURODA, Jun NAKAMURA
  • Patent number: 9315535
    Abstract: The present invention provides compounds shown by the formula: wherein Y1 is CR6 or N, Y2 is CR7 or N, Y3 is CR8 or N, R6, R7 and R8 are each independently, a hydrogen atom, halogen, cyano, substituted or unsubstituted alkyl or the like, Bx is a nucleic acid base moiety, Z1 and Z2 are each independently, a hydrogen atom, a hydroxyl protecting group or a reactive phosphorus group, R1 to R5 are each independently, a hydrogen atom, halogen, cyano, substituted or unsubstituted alkyl or the like, and n is an integer of 0 to 3, or salts thereof, that are novel nucleosides or nucleotides that can be useful as materials for synthesizing nucleic acid pharmaceuticals.
    Type: Grant
    Filed: February 17, 2014
    Date of Patent: April 19, 2016
    Assignee: SHIONOGI & CO., LTD.
    Inventors: Yasunori Mitsuoka, Akira Kugimiya, Aiko Yamashita
  • Publication number: 20150368287
    Abstract: The present invention provides compounds shown by the formula: wherein Y1 is CR6 or N, Y2 is CR7 or N, Y3 is CR8 or N, R6, R7 and R8 are each independently, a hydrogen atom, halogen, cyano, substituted or unsubstituted alkyl or the like, Bx is a nucleic acid base moiety, Z1 and Z2 are each independently, a hydrogen atom, a hydroxyl protecting group or a reactive phosphorus group, R1 to R5 are each independently, a hydrogen atom, halogen, cyano, substituted or unsubstituted alkyl or the like, and n is an integer of 0 to 3, or salts thereof, that are novel nucleosides or nucleotides that can be useful as materials for synthesizing nucleic acid pharmaceuticals.
    Type: Application
    Filed: February 17, 2014
    Publication date: December 24, 2015
    Applicant: SHIONOGI & CO., LTD.
    Inventors: Yasunori MITSUOKA, Akira KUGIMIYA, Aiko YAMASHITA
  • Publication number: 20150337002
    Abstract: The present invention provides compounds shown by the formula: wherein Y1-Y2 is S(?O)2—NR6, NR6—S(?O)2 or the like, R6 is a hydrogen atom, substituted or unsubstituted alkyl or the like, Bx is a nucleic acid base moiety, Z1 and Z2 are each independently, a hydrogen atom, a hydroxyl protecting group or a reactive phosphorus group, R1 to R5 are each independently, a hydrogen atom, halogen, cyano, substituted or unsubstituted alkyl or the like, and n is an integer of 0 to 3, or salts thereof, that are novel nucleosides or nucleotides that can be useful as materials for synthesizing nucleic acid pharmaceuticals.
    Type: Application
    Filed: January 14, 2014
    Publication date: November 26, 2015
    Applicants: SHIONOGI & CO., LTD., OSAKA UNIVERSITY
    Inventors: Satoshi OBIKA, Yasunori MITSUOKA
  • Patent number: 8927721
    Abstract: The present invention provides, for example, the following compound: wherein ring Z is pyridine or a carbocycle, each of which is substituted or unsubstituted, ring A is a carbocycle or a heterocycle, each of which is substituted or unsubstituted, R1 is substituted or unsubstituted alkyl or the like, R2a, R2b, R4a and R4b are each independently hydrogen or substituted or unsubstituted alkyl or the like, its pharmaceutically acceptable salt or a solvate thereof having an effect of inhibiting amyloid ? production, especially a BACE1 inhibitory activity, and useful as a medicament for treating diseases induced by production, secretion or deposition of amyloid ? proteins.
    Type: Grant
    Filed: October 27, 2011
    Date of Patent: January 6, 2015
    Assignee: Shionogi & Co., Ltd.
    Inventors: Yasunori Mitsuoka, Yuuji Kooriyama
  • Patent number: 8883779
    Abstract: The present invention provides a compound of formula (I): wherein —X? is —CR7? or —N?, ring B is a substituted or unsubstituted carbocycle or a substituted or unsubstituted heterocycle, R1 is substituted or unsubstituted alkyl or the like, R2 a and R2 b are each independently hydrogen, substituted or unsubstituted alkyl or the like, R3 and R4 are each independently hydrogen, halogen, substituted or unsubstituted alkyl or the like, R5 is hydrogen, substituted or unsubstituted alkyl or the like, each R6 is independently halogen, hydroxy, substituted or unsubstituted alkyl or the like, R7 is hydrogen, halogen, hydroxy, substituted or unsubstituted alkyl or the like, p is an integer of 0 to 3, or a pharmaceutically acceptable salt thereof which has an effect of inhibiting amyloid ? production, especially an effect of inhibiting BACE1, and which is useful as a therapeutic or prophylactic agent for diseases induced by production, secretion and/or deposition of amyloid ? proteins.
    Type: Grant
    Filed: April 25, 2012
    Date of Patent: November 11, 2014
    Assignee: Shinogi & Co., Ltd.
    Inventors: Moriyasu Masui, Yasunori Mitsuoka, Syuhei Yoshida, Ken-ichi Kusakabe, Naohiro Onodera, Noriyuki Kurose
  • Publication number: 20140051691
    Abstract: The present invention provides a compound of formula (I): wherein —X? is —CR7? or —N?, ring B is a substituted or unsubstituted carbocycle or a substituted or unsubstituted heterocycle, R1 is substituted or unsubstituted alkyl or the like, R2 a and R2 b are each independently hydrogen, substituted or unsubstituted alkyl or the like, R3 and R4 are each independently hydrogen, halogen, substituted or unsubstituted alkyl or the like, R5 is hydrogen, substituted or unsubstituted alkyl or the like, each R6 is independently halogen, hydroxy, substituted or unsubstituted alkyl or the like, R7 is hydrogen, halogen, hydroxy, substituted or unsubstituted alkyl or the like, p is an integer of 0 to 3, or a pharmaceutically acceptable salt thereof which has an effect of inhibiting amyloid ? production, especially an effect of inhibiting BACE1, and which is useful as a therapeutic or prophylactic agent for diseases induced by production, secretion and/or deposition of amyloid ? proteins.
    Type: Application
    Filed: April 25, 2012
    Publication date: February 20, 2014
    Applicant: SHIONOGI & CO., LTD.
    Inventors: Moriyasu Masui, Yasunori Mitsuoka, Syuhei Yoshida, Ken-ichi Kusakabe, Naohiro Onodera, Noriyuki Kurose
  • Publication number: 20130217705
    Abstract: The present invention provides, for example, the following compound: wherein ring Z is pyridine or a carbocycle, each of which is substituted or unsubstituted, ring A is a carbocycle or a heterocycle, each of which is substituted or unsubstituted, R1 is substituted or unsubstituted alkyl or the like, R2a, R2b, R4a and R4b are each independently hydrogen or substituted or unsubstituted alkyl or the like, its pharmaceutically acceptable salt or a solvate thereof having an effect of inhibiting amyloid ? production, especially a BACE1 inhibitory activity, and useful as a medicament for treating diseases induced by production, secretion or deposition of amyloid ? proteins.
    Type: Application
    Filed: October 27, 2011
    Publication date: August 22, 2013
    Applicant: SHIONOGI & CO., LTD.
    Inventors: Yasunori Mitsuoka, Yuuji Kooriyama
  • Publication number: 20120071475
    Abstract: Provided is a compound or a pharmaceutically acceptable salt thereof which inhibits the activity of PI3K to regulate many biological processes including the growth, differentiation, survival, proliferation, migration, metabolism, and the like of cells and is therefore useful for the prophylaxis/therapy of diseases including inflammatory diseases, arteriosclerosis, vascular/circulatory diseases, cancer/tumors, immune system diseases, cell proliferative diseases, infectious diseases, and the like. The above problem was solved by providing a urea derivative shown in the present specification, or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: April 26, 2010
    Publication date: March 22, 2012
    Applicant: SHIONOGI & CO., LTD.
    Inventors: Daisuke Taniyama, Yasunori Mitsuoka, Kayoko Hata
  • Publication number: 20120059162
    Abstract: Provided are a compound represented by general formula (1) and having a TTK inhibitory action and a medicine containing the compound. In formula (1), (X, Y, V, W) is (—N?, ?CR1—, ?N—, —CR7?), (—CR2?, ?N—, ?N—, —CR7?), etc.; A is an (un)substituted aromatic hydrocarbon ring, etc.; L is a single bond, —C(?O)—NRA—, etc.; Z is a group represented by the formula —NR3R4 or a group represented by the formula —OR5; R1 to R3, R6, and R7 each is a hydrogen atom, etc.; R4 and R5 each is an (un)substituted alkyl, etc.; and R8 is an (un)substituted cycloalkyl, etc.
    Type: Application
    Filed: July 27, 2011
    Publication date: March 8, 2012
    Applicant: Oncotherapy Science, Inc.
    Inventors: Ken-ichi Kusakabe, Hiroshi Yoshida, Kohei Nozu, Hiroshi Hashizume, Genta Tadano, Jun Sato, Yuusuke Tamura, Yasunori Mitsuoka
  • Publication number: 20110230472
    Abstract: It is an object of the present invention to provide a compound or a pharmaceutically acceptable salt thereof which inhibits the activity of PI3K to regulate many biological processes including the growth, differentiation, survival, proliferation, migration, metabolism, and the like of cells and is therefore useful for the prophylaxis/therapy of diseases including inflammatory diseases, arteriosclerosis, vascular/circulatory diseases, cancer/tumors, immune system diseases, cell proliferative diseases, infectious diseases, and the like. The above problem was solved by providing a ring-fused azole compound shown in the present specification, or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: August 25, 2009
    Publication date: September 22, 2011
    Applicant: Shionogi & Co., Ltd.
    Inventors: Yasunori Mitsuoka, Manami Masuda, Daisuke Taniyama
  • Publication number: 20110105457
    Abstract: The purpose of the present invention is to provide a compound or a pharmaceutically acceptable salt thereof which inhibits the activity of PI3K to regulate many biological processes including the growth, differentiation, survival, proliferation, migration, metabolism, and the like of cells and is therefore useful for the prevention/treatment of diseases including inflammatory diseases, arteriosclerosis, vascular/circulatory diseases, cancer/tumors, immune system diseases, cell proliferative diseases, infectious diseases, and the like. This was achieved by providing a substituted 2-amino-5,6-nitrogenated fused ring compound shown in the present specification, or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: April 16, 2009
    Publication date: May 5, 2011
    Inventors: Daisuke Taniyama, Kazuya Kano, Kazuya Okamoto, Masahiko Fujioka, Yasunori Mitsuoka